Depending on the health system context, the need for specialized human resources, healthcare services, diagnostics, and treatments can significantly increase the financial costs of expanding access to PD1/PD-L1 inhibitors for advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.